Press releases
Welcome to
SynAct Pharma
Treating Inflammation through Resolution Therapy
The ADVANCE data supports both business development and moving toward Phase 3 development
For phase 3 design and regulatory interactions: Clarity on safety profile, duration of treatment, and expected dosing
For partnering:
Clarity on competitive profile and potential outcomes relevant for HCPs and payers
Watch management explain the topline results
Our Team
Meet our team of entrepreneurs and innovative scientists with vast experience from biotech.
Our Science
Our approach is centered on resolving inflammation and thereby limiting the risk for immunosuppression.
Explore the science that underpins or development strategy and clinical programs.
Disease Areas
Inflammatory conditions represent a significant unmet medical need.
Resolution of inflammation provide opp0rtunities for treating a wide range of diseases.
Development Programs
Explore our development pipeline, including our lead candidate resomelagon (API189).
News and Media
Find our press releases, media coverage, and corporate updates. Stay connected to SynAct Pharma’s journey and key developments.
Latest news and press releases
Subscribe to press releases
and reports
Loading...